RP-HPLC Method Development and Validation for Simultaneous Determination of Sofosbuvir and Ledipasvir: A Pharmaceutical Application Study

The objective of the present work was to develop a simple, precise, accurate, reproducible, and specific reversed-phase high performance liquid chromatographic method for the simultaneous determination of sofosbuvir and ledipasvir in pharmaceutical dosage form. The HPLC system (Shimadzu, LC-2030) consisted of Hypersil ODS - C18 (250 mm, 4.6 mm, 5 μm- Thermo Scientific) was used for the isocratic elution using mobile phase composed of sodium phosphate buffer (pH 3.5) and acetonitrile in the ratio of 40:60% (v/v). Both sofosbuvir and ledipasvir were detected at 260 nm with a flow rate of 1 mL/min. The mean retention time of sofosbuvir was 3.094, whereas ledipasvir was 6.22 minutes. A linear relationship was found in the concentration ranged from 0.54 to 162 μg/mL for sofosbuvir (r2 = 0.9993) and 0.14 to 42 μg/mL for ledipasvir (r2 = 0.9994). The RSD values for recovery test were found 0.99% for sofosbuvir and 0.22% for ledipasvir. The lower limit of detection (LOD) were 0.054 mcg/mL and 0.012 mcg/mL, and the limit of quantification (LOQ) were 0.135 mcg/mL and 0.030 mcg/mL for sofosbuvir and ledipasvir, respectively. The method was successfully applied to the assay and in-vitro dissolution studies of sofosbuvir and ledipasvir in tablet dosage form and all the results were found within the acceptance limits.